Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time the study begins looking at their records
- People who have been formally diagnosed with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle becomes abnormally thick, blocking blood flow)
- People who were prescribed a medication called mavacamten for this heart condition at one of the study sites, between 28 April 2022 and 31 December 2024
- People who have never been enrolled in an interventional clinical trial (a trial testing a treatment) involving a type of heart medication called a cardiac myosin inhibitor — though having taken part in observational studies (where researchers only observe, not treat) is allowed
- People who were not enrolled in any interventional clinical trial at the time the study begins reviewing their records
- For the survey part of the study only: people who are also able to read and understand English and have access to a computer or smartphone to complete an online survey
Who may not be able to join:
- There are no specific exclusion criteria listed beyond not meeting all of the inclusion criteria above
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Participant blood pressure (both systolic and diastolic); Date of diagnosis of hypertrophic cardiomyopathy; Hypertrophic cardiomyopathy genetic testing results; Family history of hypertrophic cardiomyopathy; Family history of Sudden Cardiac Death (SCD); Participant comorbidities (cardiovascular and non-cardiovascular ); Type of prior surgeries and procedures; Participant New York Heart Association (NYHA) class category; Change in participant New York Heart Association (NYHA) class from baseline; Duration of mavacamten treatment; Number of mavacamten dose titrations; Type of mavacamten dose tri...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.